Skip to main content
Top
Published in:

Open Access 01-12-2024 | Research

Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease

Authors: Chiara Giuseppina Bonomi, Caterina Motta, Martina Gaia Di Donna, Martina Poli, Marzia Nuccetelli, Sergio Bernardini, Nicola Biagio Mercuri, Giacomo Koch, Alessandro Martorana

Published in: Alzheimer's Research & Therapy | Issue 1/2024

Login to get access

Abstract

Background

The role of Vascular risk factors (VRFs) in the progression of Alzheimer’s Disease (AD) and cognitive decline remains to be elucidated, with previous studies resulting in conflicting findings. The possible impact of age-specific mechanisms of resilience/vulnerability is an under addressed issue. We evaluated the association of VRFs with markers of amyloid deposition, neurodegeneration, and blood-brain-barrier (BBB) permeability (Albumin quotient, Qalb), stratifying patients into early-onset (< 65, EOAD), classic late-onset (65–75, cLOAD) and very late-onset (> 75, vLOAD), to evaluate the moderating effect of age of onset. Moreover, we explored the effects of VRFs on cognitive decline at one year follow-up (ΔMMSE).

Methods

For 368 patients with biologically confirmed AD, we computed eight risk factors in a composite measure of cumulative vascular risk (vascular score, VS). Stratifying patients according to age of onset, we regressed VS and main individual VRFs on p-tau/Aβ42, t-tau and Qalb, and used bootstrapped mediation analysis to test direct and indirect associations of VS with t-tau, using Qalb as mediator. In a subset of 105 patients, we performed multivariate backward regressions to assess the effects of sex, APOE, Qalb, VS, p-tau/Aβ42 and t-tau on ΔMMSE.

Results

VS was positively associated with CSF t-tau in more vulnerable groups burdened by more aggressive disease progression (EOAD: β = 0.256, p = 0.019) or aging (vLOAD: β = 0.007, p < 0.001). Conversely, in patients with classic age of onset VS was associated with higher BBB permeability (cLOAD: β = 0.173, p = 0.015), which simultaneously causes the decrease of CSF t-tau, as a possible resilience response. Cognitive decline was not associated with VS in any of the subgroups. Instead, it was affected by both higher CSF t-tau and increased Qalb values in those with very early or very late onset (EOAD and vLOAD), but by Qalb alone in patients with classic age of onset, where CSF t-tau levels might be buffered by BBB permeability.

Conclusions

Our results show that age of onset weighs on the heterogeneous effects played by VRFs in AD, which do not seem to have direct impact on cognitive decline. These findings stress the importance of a tailored patient-centered approach to the application of vascular prevention strategies in AD.
Literature
1.
go back to reference Alzheimer’s Disease International. World Alzheimer Report 2023: Reducing Dementia Risk: Never too early, never too late. 2023. Alzheimer’s Disease International. World Alzheimer Report 2023: Reducing Dementia Risk: Never too early, never too late. 2023.
2.
go back to reference Hampel H, Au R, Mattke S, van der Flier WM, Aisen P, Apostolova L, et al. Designing the next-generation clinical care pathway for Alzheimer’s disease. Nat Aging 2022. 2022;2(8):8. Hampel H, Au R, Mattke S, van der Flier WM, Aisen P, Apostolova L, et al. Designing the next-generation clinical care pathway for Alzheimer’s disease. Nat Aging 2022. 2022;2(8):8.
3.
go back to reference Coulthard EJ, Love S. A broader view of dementia: multiple co-pathologies are the norm. Brain. 2018;141(7):1894–7.CrossRefPubMed Coulthard EJ, Love S. A broader view of dementia: multiple co-pathologies are the norm. Brain. 2018;141(7):1894–7.CrossRefPubMed
4.
go back to reference Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–93.CrossRefPubMedPubMedCentral Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–93.CrossRefPubMedPubMedCentral
5.
go back to reference Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer’s disease, and dementia in older persons. Biochim et Biophys Acta - Mol Basis Disease. 2016;1862(5):878–86.CrossRef Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer’s disease, and dementia in older persons. Biochim et Biophys Acta - Mol Basis Disease. 2016;1862(5):878–86.CrossRef
6.
go back to reference Coomans EM, van Westen D, Pichet Binette A, Strandberg O, Spotorno N, Serrano GE et al. Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation. Brain. 2023. Coomans EM, van Westen D, Pichet Binette A, Strandberg O, Spotorno N, Serrano GE et al. Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation. Brain. 2023.
7.
go back to reference Cogswell PM, Lundt ES, Therneau TM, Mester CT, Wiste HJ, Graff-Radford J et al. Evidence against a temporal association between cerebrovascular disease and Alzheimer’s disease imaging biomarkers. Nature Communications 2023 14:1. 2023;14(1):1–12. Cogswell PM, Lundt ES, Therneau TM, Mester CT, Wiste HJ, Graff-Radford J et al. Evidence against a temporal association between cerebrovascular disease and Alzheimer’s disease imaging biomarkers. Nature Communications 2023 14:1. 2023;14(1):1–12.
8.
go back to reference Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer’s disease. Alzheimer’s Dement. 2015;11(4):394–e4031.CrossRef Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer’s disease. Alzheimer’s Dement. 2015;11(4):394–e4031.CrossRef
10.
go back to reference Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction—the disregarded partner of Alzheimer’s disease. Alzheimer’s Dement. 2019;15(1):158–67.CrossRef Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction—the disregarded partner of Alzheimer’s disease. Alzheimer’s Dement. 2019;15(1):158–67.CrossRef
11.
go back to reference Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Weiner MW, et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 2016. 2016;7(1):1. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Weiner MW, et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 2016. 2016;7(1):1.
12.
go back to reference Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 2019. 2019;25(2):2. Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 2019. 2019;25(2):2.
13.
go back to reference Barisano G, Montagne A, Kisler K, Schneider JA, Wardlaw JM, Zlokovic BV. Blood-brain barrier link to human cognitive impairment and Alzheimer’s Disease. Nat Cardiovasc Res. 2022;1(2):108.CrossRefPubMedPubMedCentral Barisano G, Montagne A, Kisler K, Schneider JA, Wardlaw JM, Zlokovic BV. Blood-brain barrier link to human cognitive impairment and Alzheimer’s Disease. Nat Cardiovasc Res. 2022;1(2):108.CrossRefPubMedPubMedCentral
14.
go back to reference Puig-Pijoan A, Jimenez-Balado J, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, Contador J, et al. Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: a longitudinal study in a memory unit clinical cohort. Alzheimer’s & Dementia; 2023. Puig-Pijoan A, Jimenez-Balado J, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, Contador J, et al. Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: a longitudinal study in a memory unit clinical cohort. Alzheimer’s & Dementia; 2023.
15.
go back to reference He JT, Zhao X, Xu L, Mao CY. Vascular risk factors and Alzheimer’s Disease: blood-brain barrier disruption, metabolic syndromes, and Molecular Links. J Alzheimer’s Disease. 2020;73(1):39–58.CrossRef He JT, Zhao X, Xu L, Mao CY. Vascular risk factors and Alzheimer’s Disease: blood-brain barrier disruption, metabolic syndromes, and Molecular Links. J Alzheimer’s Disease. 2020;73(1):39–58.CrossRef
16.
go back to reference Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimer’s Dementia: J Alzheimer’s Association. 2015;11(6):710–7.CrossRef Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimer’s Dementia: J Alzheimer’s Association. 2015;11(6):710–7.CrossRef
17.
go back to reference Pettigrew C, Soldan A, Wang J, Wang MC, Arthur K, Moghekar A, et al. Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline. Neurology. 2020;95(23):e3093–103.CrossRefPubMedPubMedCentral Pettigrew C, Soldan A, Wang J, Wang MC, Arthur K, Moghekar A, et al. Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline. Neurology. 2020;95(23):e3093–103.CrossRefPubMedPubMedCentral
18.
go back to reference Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, et al. Interactive associations of vascular risk and β-Amyloid Burden with Cognitive decline in clinically normal Elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75(9):1124–31.CrossRefPubMedPubMedCentral Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, et al. Interactive associations of vascular risk and β-Amyloid Burden with Cognitive decline in clinically normal Elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75(9):1124–31.CrossRefPubMedPubMedCentral
19.
go back to reference Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302–9.CrossRefPubMed Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302–9.CrossRefPubMed
20.
go back to reference Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443–50.CrossRefPubMedPubMedCentral Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443–50.CrossRefPubMedPubMedCentral
21.
go back to reference Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021;144(7):2186–98.CrossRefPubMedPubMedCentral Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021;144(7):2186–98.CrossRefPubMedPubMedCentral
22.
go back to reference Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC et al. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females. Brain. 2023. Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC et al. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females. Brain. 2023.
23.
go back to reference Johnston R, Jones K, Manley D. Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour. Qual Quantity. 2018;52(4):1957–76.CrossRef Johnston R, Jones K, Manley D. Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour. Qual Quantity. 2018;52(4):1957–76.CrossRef
24.
go back to reference Sapkota S, Erickson K, Fletcher E, Tomaszewski Farias SE, Jin LW, DeCarli C. Vascular Risk Predicts Plasma Amyloid β 42/40 Through Cerebral Amyloid Burden in Apolipoprotein E ε4 Carriers. Stroke [Internet]. 2023 May 1 [cited 2023 Jun 9];54(5):1227–35. https://pubmed.ncbi.nlm.nih.gov/37021572/ Sapkota S, Erickson K, Fletcher E, Tomaszewski Farias SE, Jin LW, DeCarli C. Vascular Risk Predicts Plasma Amyloid β 42/40 Through Cerebral Amyloid Burden in Apolipoprotein E ε4 Carriers. Stroke [Internet]. 2023 May 1 [cited 2023 Jun 9];54(5):1227–35. https://​pubmed.​ncbi.​nlm.​nih.​gov/​37021572/​
25.
go back to reference Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–9.CrossRefPubMed Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–9.CrossRefPubMed
26.
go back to reference Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Lowe VJ, Graff-Radford J, et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017;82(5):706–18.CrossRefPubMedPubMedCentral Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Lowe VJ, Graff-Radford J, et al. Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol. 2017;82(5):706–18.CrossRefPubMedPubMedCentral
27.
go back to reference Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.CrossRefPubMedPubMedCentral Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.CrossRefPubMedPubMedCentral
28.
go back to reference Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer’s disease is associated with greater pathologic burden. J Geriatr Psychiatr Neurol. 2007;20(1):29–33.CrossRef Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer’s disease is associated with greater pathologic burden. J Geriatr Psychiatr Neurol. 2007;20(1):29–33.CrossRef
29.
go back to reference Ritchie K, Ritchie CW, Jaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer’s disease really a disease of midlife? Alzheimer’s & dementia: Translational Research &. Clin Interventions. 2015;1(2):122. Ritchie K, Ritchie CW, Jaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer’s disease really a disease of midlife? Alzheimer’s & dementia: Translational Research &. Clin Interventions. 2015;1(2):122.
30.
go back to reference Boivin-Proulx LA, Brouillette J, Dorais M, Perreault S. Association between cardiovascular diseases and dementia among various age groups: a population-based cohort study in older adults. Sci Rep. 2023;13(1). Boivin-Proulx LA, Brouillette J, Dorais M, Perreault S. Association between cardiovascular diseases and dementia among various age groups: a population-based cohort study in older adults. Sci Rep. 2023;13(1).
31.
go back to reference Andjelkovic AV, Situ M, Citalan-Madrid AF, Stamatovic SM, Xiang J, Keep RF. Blood-brain barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments. Stroke. 2023;54(3):661–72.CrossRefPubMedPubMedCentral Andjelkovic AV, Situ M, Citalan-Madrid AF, Stamatovic SM, Xiang J, Keep RF. Blood-brain barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments. Stroke. 2023;54(3):661–72.CrossRefPubMedPubMedCentral
32.
go back to reference Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776–92.CrossRefPubMedPubMedCentral Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776–92.CrossRefPubMedPubMedCentral
33.
go back to reference Ricci F, Martorana A, Bonomi CG, Serafini C, Mercuri NB, Koch G, et al. Effect of vascular risk factors on blood-brain barrier and cerebrospinal fluid biomarkers along the Alzheimer’s Disease Continuum: a retrospective observational study. J Alzheimer’s Disease. 2023;Preprint(Preprint):1–9. Ricci F, Martorana A, Bonomi CG, Serafini C, Mercuri NB, Koch G, et al. Effect of vascular risk factors on blood-brain barrier and cerebrospinal fluid biomarkers along the Alzheimer’s Disease Continuum: a retrospective observational study. J Alzheimer’s Disease. 2023;Preprint(Preprint):1–9.
34.
go back to reference Cheng YW, Chiu MJ, Chen YF, Cheng TW, Lai YM, Chen TF. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease. Alzheimer’s Res Therapy. 2020;12(1):1–10. Cheng YW, Chiu MJ, Chen YF, Cheng TW, Lai YM, Chen TF. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease. Alzheimer’s Res Therapy. 2020;12(1):1–10.
35.
go back to reference Kim J, Woo SY, Kim S, Jang H, Kim J, Kim J, et al. Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease. Alzheimer’s Res Therapy. 2021;13(1):1–10. Kim J, Woo SY, Kim S, Jang H, Kim J, Kim J, et al. Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease. Alzheimer’s Res Therapy. 2021;13(1):1–10.
36.
go back to reference Luo X, Hong H, Li K, Zeng Q, Wang S, Li Z, et al. Distinct cerebral small vessel disease impairment in early- and late-onset Alzheimer’s disease. Ann Clin Transl Neurol. 2023;10(8):1326–37.CrossRefPubMedPubMedCentral Luo X, Hong H, Li K, Zeng Q, Wang S, Li Z, et al. Distinct cerebral small vessel disease impairment in early- and late-onset Alzheimer’s disease. Ann Clin Transl Neurol. 2023;10(8):1326–37.CrossRefPubMedPubMedCentral
37.
go back to reference Hessen E, Nordlund A, Stalhammar J, Eckerström M, Bjerke M, Eckerström C, et al. T-Tau is Associated with Objective memory decline over two years in persons seeking help for subjective cognitive decline: a report from the Gothenburg-Oslo MCI Study. J Alzheimer’s Disease. 2015;47(3):619–28.CrossRef Hessen E, Nordlund A, Stalhammar J, Eckerström M, Bjerke M, Eckerström C, et al. T-Tau is Associated with Objective memory decline over two years in persons seeking help for subjective cognitive decline: a report from the Gothenburg-Oslo MCI Study. J Alzheimer’s Disease. 2015;47(3):619–28.CrossRef
38.
go back to reference Bruno M, Bonomi CG, Ricci F, Di Donna MG, Mercuri NB, Koch G, et al. Blood–brain barrier permeability is associated with different neuroinflammatory profiles in Alzheimer’s disease. Eur J Neurol. 2024;31(1):e16095.CrossRefPubMed Bruno M, Bonomi CG, Ricci F, Di Donna MG, Mercuri NB, Koch G, et al. Blood–brain barrier permeability is associated with different neuroinflammatory profiles in Alzheimer’s disease. Eur J Neurol. 2024;31(1):e16095.CrossRefPubMed
39.
go back to reference Ali DG, Abner EL, Bahrani AA, El Khouli R, Gold BT, Jiang Y, et al. Amyloid-PET and White Matter Hyperintensities have Independent effects on Baseline cognitive function and synergistic effects on Longitudinal executive function. Brain Sci. 2023;13(2):218.CrossRefPubMedPubMedCentral Ali DG, Abner EL, Bahrani AA, El Khouli R, Gold BT, Jiang Y, et al. Amyloid-PET and White Matter Hyperintensities have Independent effects on Baseline cognitive function and synergistic effects on Longitudinal executive function. Brain Sci. 2023;13(2):218.CrossRefPubMedPubMedCentral
40.
go back to reference Ruthirakuhan M, Cogo-Moreira H, Swardfager W, Herrmann N, Lanctot KL, Black SE. Cardiovascular Risk factors and risk of Alzheimer Disease and Mortality: a latent class Approach. J Am Heart Association. 2023;12(1):25724.CrossRef Ruthirakuhan M, Cogo-Moreira H, Swardfager W, Herrmann N, Lanctot KL, Black SE. Cardiovascular Risk factors and risk of Alzheimer Disease and Mortality: a latent class Approach. J Am Heart Association. 2023;12(1):25724.CrossRef
41.
go back to reference Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63.CrossRefPubMed Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63.CrossRefPubMed
Metadata
Title
Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease
Authors
Chiara Giuseppina Bonomi
Caterina Motta
Martina Gaia Di Donna
Martina Poli
Marzia Nuccetelli
Sergio Bernardini
Nicola Biagio Mercuri
Giacomo Koch
Alessandro Martorana
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2024
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-024-01617-2

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more